Common use of Main Clause in Contracts

Main. As we agreed, this letter serves to clarify formally that Ciba no longer has rights to the listed cases, and, therefore, is no longer responsible for associated patent costs incurred after November 3, 1995. Thanks again. With best regards, /s/ ▇▇▇▇▇▇ ▇. ▇▇▇▇▇ cc: A. Main ▇. ▇▇▇▇▇ (with duplicate original) ▇▇▇▇▇▇ ▇▇▇▇▇, Ph.D. Director of Licensing Ciba-Geigy Corporation ▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇ Summit, NJ 07901 Re: ▇▇▇▇▇▇ Portfolio Dear ▇▇▇▇▇▇: The purpose of this letter is to clarify that Ciba has no further rights in the following cases and will no longer be responsible for patent costs incurred after November 3, 1995. Upon request of The Regents, Ciba-Geigy Corporation will assign its interest in the co-owned case UC 92-383. Patent costs for UC 93-268 will be governed by our option agreement. ▇▇ ▇▇▇▇ ▇▇-▇▇▇ ▇▇▇▇▇▇ for Selected Methionine Starvation of Malignant Cells in Mammals UC Case ▇▇-▇▇▇ ▇▇▇▇▇▇ for Detection of Methylthioadenosine Phosphorylase Deficiency in Mammalian Cells UC Case 92-296 Allergy Gene Immunotherapy and Cancer Gene Immunotherapy Projects UC Case ▇▇-▇▇▇ ▇▇▇▇▇▇ for Reduction of Endotoxin Contamination of Plasmid Derived DNA UC Case 94-029 Compounds for Inhibition of Inflammation and Fibrosis UC Case ▇▇-▇▇▇ ▇▇▇▇▇ Suppressor Gene and Methods for Detection of Cancer, Monitoring of Tumor Progression and Cancer Treatment UC Case 96-114 Non-coding Regions of DNA Expression Vectors Necessary for Gene Immunization ▇▇▇▇▇▇ ▇. ▇▇▇▇▇, Ph.D. May 14, 1996 Please indicate your agreement with this by countersigning one original of this letter and returning it to me at your earliest convenience. Sincerely, /s/ ▇▇▇▇▇ ▇. ASTON AGREED TO: CIBA-GEIGY CORPORATION /s/ ▇▇▇▇ MAIN /MJM Name: ▇▇▇▇ Main Title: Senior Vice President, Research Date: 5/29/96 This Cooperative Technology Administration Agreement (“Agreement”) is made as of this 19th day of May, 2000, by and between the United States Department of Veterans Affairs (hereinafter referred to as “VA”), as represented by the Technology Transfer Program, Office of Research and Development, having an address at ▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇. ▇., ▇▇▇▇▇▇▇▇▇▇, D. C. 20420, and The Regents of the University of California, as represented by the Office of Technology Transfer, having an address at ▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇-▇▇▇▇ (“University”).